Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes

Trial Profile

Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms HARUKAS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top